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Abstract
Background:  Human biomonitoring (HBM) has rapidly gained importance. In some
epidemiological studies, the measurement and use of biomarkers of exposure, susceptibility and
disease have replaced traditional environmental indicators. While in HBM, ethical issues have
mostly been addressed in terms of informed consent and confidentiality, this paper maps out a
larger array of societal issues from an epistemological perspective, i.e. bringing into focus the
conditions of how and what is known in environmental health science.
Methods: In order to analyse the effects of HBM and the shift towards biomarker research in the
assessment of environmental pollution in a broader societal context, selected analytical
frameworks of science studies are introduced. To develop the epistemological perspective,
concepts from "biomedical platform sociology" and the notion of "epistemic cultures" and "thought
styles" are applied to the research infrastructures of HBM. Further, concepts of "biocitizenship" and
"civic epistemologies" are drawn upon as analytical tools to discuss the visions and promises of
HBM as well as related ethical problematisations.
Results:  In human biomonitoring, two different epistemological cultures meet; these are
environmental science with for instance pollution surveys and toxicological assessments on the one
hand, and analytical epidemiology investigating the association between exposure and disease in
probabilistic risk estimation on the other hand. The surveillance of exposure and dose via
biomarkers as envisioned in HBM is shifting the site of exposure monitoring to the human body.
Establishing an HBM platform faces not only the need to consider individual decision autonomy as
an ethics issue, but also larger epistemological and societal questions, such as the mode of evidence
demanded in science, policy and regulation.
Conclusion: The shift of exposure monitoring towards the biosurveillance of human populations
involves fundamental changes in the ways environment, health and disease are conceptualised; this
may lead to an individualisation of responsibilities for health risks and preventive action. Attention
to the conditions of scientific knowledge generation and to their broader societal context is critical
in order to make HBM contribute to environmental justice.
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Background
The field of environmental health research is facing tre-
mendous changes, as new biomarker techniques are
developed in the biosciences: Biomarkers of exposure,
susceptibility and effect have rapidly gained importance
and feature prominent in many studies in environmental
epidemiology. While environmental sciences have
focused on monitoring exposure levels in soil, water and
air, environmental exposures are increasingly measured
via biological markers within the human body. In human
biomonitoring (HBM), environmental field sciences meet
concepts and methodologies from epidemiology and bio-
medicine.
Research into the use of biomarkers in environmental
health is currently funded by many government agencies
worldwide. The increasing importance of biomarkers in
environmental health research is reflected in a number of
seminal articles on HBM [1-6]. As part of national envi-
ronment and health programmes, HBM initiatives have
been pursued in several European countries from the
1980s onwards to survey the intake of anthropogenic
chemicals [7-9]. More recently, larger biomonitoring
projects were implemented in member states of the Euro-
pean Union to support standardised data collection and
data processing. In the framework of its Environment and
Health Action Plan 2004–2010 the European Commission
initiated the development of a coherent approach to HBM
[10,11].
At this moment of European harmonisation initiatives,
reviewing the conceptual frameworks of HBM from a sci-
ence studies perspective can inform the choices to be
made both in research and in regulatory planning. In par-
ticular in view of the often stated need to fill knowledge
gaps on the link between environment and health and the
"ultimate goal [...] to develop an environment and health
'cause-effect framework'"  for policy [12], attention to the
specific modes of knowledge production is important. To
analyse conceptual frameworks and research practices, sci-
ence studies can offer a range of tools, which include his-
torical contextualisation, the ethnographic and
microsociological study of single institutions, of particu-
lar laboratories or research networks and the analysis of
interaction and co-production between science and soci-
ety [13,14]. It is only recently that science studies accounts
of environmental health research – at the intersection of
public health and environmental science – begin to
emerge. Mitman et al. [15] state that much of the most
recent environmental health history has fallen between
the cracks of environmental history, geography, history of
science, medical history and science studies.
The human body became an object of quantitative science
in the context of 19th century biometry and physical
anthropology; metrics were applied to medicine and
physiology as well as to all corners of science and society
with avalanches of numerical data produced, including
first censuses as large scale inventories of populations [16-
18]. In the context of occupational medicine, techniques
to measure the uptake of chemical substances directly in
human body fluids were developed in the early 20th cen-
tury; measurements of lead and benzene metabolites were
conducted by industry in the 1930s [8]. Large scale HBM
was first and mainly practiced as workforce surveillance
and later became part of regulatory requirements for some
industrial sectors, mostly the chemical industry. Employ-
ers and industrial medicine have increasingly monitored
workers' intake of hazardous chemicals and industrial
medicine had an important influence on the development
of the environmental movement in the second half of the
20th century [19]. Human biomonitoring can be situated
in a tradition of occupational medicine that developed
under the conditions of industrial hygiene as an applied
science.
While the contemporary extension of HBM from occupa-
tional medicine to public health has often been framed in
terms of an environmental justice agenda [20,21] aimed
at reducing inequities in environmental health, monitor-
ing chemicals among the general population also raises a
host of societal and ethical issues, related to recruitment,
participation and confidentiality, to the use, access and
interpretation of data as well as to policy action.
This paper explores HBM and its conceptual frameworks
and research practices that build on both environmental
sciences and epidemiology; it uses science studies tools to
broaden the ethics debate to include epistemological and
societal aspects, such as the recent shift to biomarkers in
exposure assessment and related conceptual changes in
environmental health knowledge.
Methods
This analysis of human biomonitoring (HBM) and its eth-
ical problematisations focuses on the structures and
modes of knowledge generation. By concentrating on
epistemologies, this paper seeks to better understand the
structure, the limitations and the stabilisation of knowl-
edge in the field of environmental health sciences. For this
purpose, an analysis based on a review of the scientific lit-
erature at the intersection of biomonitoring, epidemiol-
ogy and environmental health from the late 1980s to
present has been conducted. Analysed materials include
published research papers on HBM in environmental sci-
ence, epidemiology and human toxicology as well as
review articles on the development of HBM and, in partic-
ular, on the use of biomarkers in epidemiological studies.
In addition to the scientific literature on HBM as available
in databases such as PubMed, reports and strategy papersEnvironmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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for instance of the European Research Council have also
been taken into account. The text analysis examined how
HBM and biomarker research delineated their goals and
scope, what kind of visions and promises become
attached to the research endeavours and how ethical
issues were problematised.
In order to explore the ethical and the broader societal
issues that arise from population biosurveillance on a
more conceptual level, this paper draws on epistemologi-
cal approaches developed in science studies, i.e. "platform
sociology" [22], "epistemic cultures" [23][24] and
"thought styles" [25], as well as on frameworks that allow
to explore the relations to citizenship concepts. While this
paper spans from knowledge production to the ways this
knowledge is taken up in policy and regulation, its point
of departure is less in the debate on ethics principles, such
as informed consent, confidentiality or the right to know
or not to know. Rather, this paper takes a closer look at the
broader societal aspects at stake in the emerging HBM
platforms for knowledge production in environmental
health.
Inspired by "platform sociology" [22], this analysis
focuses on HBM research as an emerging infrastructure
that incorporates both environmental and biomedical
research traditions. Rather than requiring shared con-
cepts, biomedical platforms are based on common techni-
cal and administrative infrastructures, which co-organise
and also regulate the production of knowledge [22]. The
standardised HBM platform is described as a distributed
research system, which extends beyond environmental
chemistry and toxicology laboratories to the health care
systems, to include population health and society as a
whole.
This paper analyses the different "epistemic cultures" of
knowledge production that meet in environmental health
sciences and in HBM in particular. The concept of "epis-
temic cultures" or "epistemological cultures" [23,24]
brings into focus the arrangements and mechanisms of
knowledge generation, the modes of knowing in different
science communities and their criteria for what counts as
scientific evidence. In order to juxtapose the "thought
styles" [25] at work in HBM, environmental science and
risk factor epidemiology will be introduced as distinct tra-
ditions for analytical purposes, although they can well
overlap in practice.
The concepts of "biosociality" [26] and "biocitizenship"
[27,28] will be employed to grasp the effects of HBM on
the governance of populations [29] and the specific con-
ditions of biosurveillance through HBM. To examine the
role of HBM in the knowledge society, the notion of "bio-
sociality", will be used to trace how social processes and
networks are reconfigured along with bioscientific catego-
ries. "Biological citizenship" as used here denotes the
shifts in the understandings of citizenship towards the
active engagement in the emerging biosociety; this
includes participation in health research as well as renego-
tiations of individual and group identities by actively
drawing for instance on genetic categories.
The configurations at the science and society interface will
be further explored by asking for "civic epistemologies", a
term introduced by Jasanoff [30] in her comparative anal-
ysis of life sciences politics as a relationship between state,
science and the public in the US and Europe. Civic episte-
mologies relate to the culturally specific, historically and
politically grounded knowledge-ways and the process
through which knowledge comes to be perceived as relia-
ble [30].
Together, these perspectives make it possible to examine
both the epistemological infrastructures and institutional-
ised practices by which knowledge is generated and
deployed as a basis for political choices in society. This
will enable a broader analysis of the bioethical debates in
HBM and, more generally, of biomedical and epidemio-
logical research.
Results and discussion
Human biomonitoring (HBM): an emerging research 
platform
Human biomonitoring (HBM) has recently been defined
as "the assessment of human exposure to an environmen-
tal chemical via the measurement of that chemical, its
metabolite(s), or reaction product(s) in human blood,
urine, milk, saliva, adipose or other tissue in individuals
taken separately but generally taken together to constitute
a population" [9].
Generating and interpreting HBM data involves a wide
range of subdisciplines, for instance those of environmen-
tal chemistry, toxicology and epidemiology, with distinct
experimental practices and conceptual frameworks. As
will be elaborated in more detail below, the ways in which
environment, health and risk are framed differ substan-
tially between these disciplines; this affects the ways in
which data are collected, made sense of and deployed in
science and for policy decisions. What ties the different
subdisciplines together in HBM, is the common infra-
structure of data collecting and the joint aim of monitor-
ing environmental determinants of health and disease.
Processing individual data in an epidemiological frame-
work, i.e. at levels of the population and subpopulations,
is a key feature to the use of HBM data; this holds for
descriptive analyses as well as for health risk assessments
and aetiologic hypothesis testing for associations between
environmental exposures and disease outcomes.Environmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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The European Environment and Health Action Plan stresses
that "biomonitoring is not an automatic instrument,
which can be considered in isolation, but has to be inte-
grated with environmental monitoring, toxicological and
ecotoxicological data and especially with the considera-
tions related to analytical epidemiology" [11]. To account
for the diversity of related disciplines, infrastructures and
practices that are brought together in this common net-
work, HBM can be described as extended "biomedical
platform" in the sense that they comprise "material and
discursive arrangements that act as the bench upon which
conventions concerning the biological or normal are con-
nected with conventions concerning the medical or the
pathological" [22]. The HBM infrastructure encompasses
databases as well as samples in biobanks, protocols for
collecting practice and analytical routines. The emerging
European HBM platform comprises a set of standardised
methods and guidelines for deriving exposure limits and
health risk estimates that enter policy decision-making.
With respect to the understanding and meaning of
biomarkers, reviews often point to gaps in knowledge,
data and validation that render interpretation difficult; for
instance background and baseline values are not available
for many ubiquitous environmental chemicals and their
metabolites [5,31]. The envisaged goal of HBM studies, as
stated in a 2005 summary report, is to establish baseline
values and distributions of body burdens of environmen-
tal chemicals in the general population; foreseen next
steps include identifying geographical clusters of elevated
concentrations of biomarkers, studying time trends and
evaluating the efficacy of regulatory action [5].
As a scientific resource, different visions and promises are
attached to the HBM platform in environmental science
and epidemiology, respectively: In environmental science,
biomarkers of exposure are understood as extension to
environmental monitoring, that will add important infor-
mation in the surveillance of actual doses. For example,
DNA adducts have for decades been researched as "bio-
logical dosimeters" that may "qualitatively indicate
increased risk of cancer" [1]. Such biological dosimeters
were anticipated to provide direct measures of environ-
mental pollutants and early detection of exposure effects,
yet the quantification and precision needed for deriving
exposure limits proved difficult to achieve; new biomark-
ers are hoped to fulfil this function.
From the perspective of epidemiology, the value and
potential of HBM is the methodological opportunity to
reduce the bias introduced with exposure misclassifica-
tion; reliance on biomarkers is therefore expected to
strengthen epidemiologic risk assessments. Some biomar-
kers of exposure are hoped to enable direct measurement
of actual combined exposures and to enable the determi-
nation of summary cumulative individual doses for epide-
miological studies. However, biomarker measurements
have also been reported to involve considerable impreci-
sion beyond laboratory performance; the reliance on sin-
gle parameters for a biomarker concentration is therefore
problematic and such imprecision can underestimate the
dose-related toxicity [32].
Thought styles and epistemic cultures in HBM: 
environmental science and epidemiology
This section juxtaposes environmental science and (risk
factor) epidemiology, as research fields that epitomise
two main and different thought styles at work in contem-
porary environmental health science and in HBM in par-
ticular. Both environmental science and epidemiology
represent empirical field sciences, yet they have developed
within different disciplinary traditions and cultures of
research. While environmental science performs descrip-
tive mapping, monitoring and reduction of exposures to
environmental chemicals, approaches of analytical epide-
miology focus on disease aetiology and assess multiple
associations between exposure and disease in statistical
inference tests. In epidemiology, contestations over cau-
sality and the respective contributions of genetic, environ-
mental, lifestyle or social "risk factors" are sorted out
through statistical modelling of these determinants.
Environmental science
Environmental sciences – such as environmental chemis-
try and engineering – focus on exposure. Key practices of
knowledge generation include developing monitoring
systems of emission sources, modelling distribution pat-
terns and pathways of environmental chemicals including
their migration and uptake. In the thought style of envi-
ronmental science, risk assessments model the dynamics
of chemicals in environmental compartments, estimate
exposure and doses at individual and collective levels;
indicators are developed, monitored and related to regu-
latory frameworks with exposure limits that are based on
toxicologic and epidemiologic assessments. Assessments
from an environmental science perspective can include
both human and ecosystem exposures. Different from
epidemiological surveillance, this kind of monitoring
does not necessarily imply immediate synthesis with
health data and aetiologic hypotheses testing; rather it
aims at precautionary risk management and exposure
reduction.
In environmental sciences, the goal of "primary preven-
tion" is the survey and control of environmental chemi-
cals rather than aetiological research. In that it focuses on
the environment as a societal issue with interventions on
the level of regulation, the conceptual framework of the
environmental science approach differs from the multipleEnvironmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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individual risk factor concept used in epidemiologic
assessments.
Epidemiology
No longer restricted to the study of infectious disease, epi-
demiology has often been described as the "basic science
of public health". In his history of epidemiologic meth-
ods, Morabia tentatively characterises epidemiology as
"population health aetiology" or "science of causation"
[33]. Since the 1960s epidemiology has put forward an
often pragmatic multifactorial approach to disease causa-
tion, which is dealt with through multivariate statistical
modelling. The contemporary field comprises many sub-
disciplines, mostly named according to the exposures or
the diseases studied – such as genetic, nutritional and
radiation epidemiology and cancer, or cardiovascular epi-
demiology.
Environmental epidemiology investigates environmental
conditions and their associations to disease outcomes
with specific study designs and the related statistical tech-
niques, for instance logistic regression modelling. While
epidemiology largely originated in the field of biometrics,
medical and social statistics and demography, the tech-
niques of proof used in epidemiology have been widely
applied from biomedicine to social sciences.
Epidemiological methods epitomise a certain thought
style at work in biomedical and clinical research and
becoming influential in public health. In particular with
"evidence-based medicine" (EBM), epidemiologic meth-
ods have developed into a general technique of testing for
association between determinants and outcomes. Rigor-
ous epidemiologic study designs have become the meth-
odological standard of proof which, like all biomedical
research, environmental health issues must pass in order
to achieve visibility. This epistemological shift to risk fac-
tor epidemiology as a powerful and robust technique has
reconfigured the framework and conditions in which
much of current environmental health research, including
HBM, is taking place. The thought style of epidemiology
shifts the framework towards conditions of proof devel-
oped in biomedical research. For HBM, this implies the
requirement to conduct analytical studies, which demand
a different set-up and data strategies than a surveillance
and monitoring system.
HBM and the intersection of environmental health research
The databases and biobanks created in HBM have been
envisioned as resources for aetiological studies of single
and combined exposures as potentially causal agents. If
however HBM data are collected mainly for the purpose of
aetiologic research, this may lead to an emphasis of
extending large-scale epidemiological studies (often initi-
ated in other contexts) at the expense of studies into
locally relevant exposure pathways. To obtain large num-
bers for aetiological investigations, existing multi-centre
studies are supplemented with biomarker variables as sur-
rogates for environmental exposure – while the exposure
history and sources then remain difficult or impossible to
trace.
To become articulated within the thought style and epis-
temic culture of analytical epidemiology, standards of
proof developed in medical decision-making are increas-
ingly drawn upon when discussing questions of causality
in environmental health. The broad application of bio-
medical criteria to environmental health issues can be
viewed as part of a more general "biomedicalisation", a
term introduced, among others, by Clarke et al. [34] to
denote the increasingly complex and multisited transfor-
mations of medicine through science and technology in
the second half of the 20th century, for instance with epi-
demiologic surveillance and risk assessment.
However, conceptual frameworks that strive to integrate
the environmental perspective into the biomedical sci-
ences have been developed in social epidemiology; with
these frameworks of causation work, social epidemiolo-
gists aim at shifting the research focus from aetiological
epidemiology and individualised risk estimates towards
more societally modifiable factors to be addressed on the
level of policy [35]. Eco-social frameworks of disease cau-
sation attempt to provide alternative models, using the
concept of embodiment, in order to better account for the
complex interaction with social and environmental fac-
tors [36]. In the development of an integrated HBM plat-
form, awareness of the conceptual framework, of the level
of data production and of the relations between biomark-
ers and pathways of exposure as well as the conditions of
knowledge and their social dimensions will be important.
Epistemological issues – what does count as evidence?
Software platforms for multi-layered data mapping of
environmental and social factors, e.g. geographic infor-
mation systems as envisaged for HBM data platforms, are
key tools to map data onto spatial or temporal grids both
in environmental research and epidemiology. Environ-
mental sciences draw extensively on mapping techniques
in the tradition of atlases – for instance in environmental
atlases or, in descriptive epidemiology, cancer atlases.
Such public health maps are often traced back to John
Snow's paradigmatic epidemiological study on cholera
and contaminated water in 19th century London.
Different from this type of descriptive accounts of aggre-
gated data, analytical epidemiology is about aetiological
hypotheses testing and statistical inference based on data-
sets with individual level records that allow control for
confounders. Evidence-based medicine sorts out epidemi-Environmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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ologic results by study design – from bench research and
singular expert opinions (which are understood as
belonging to the lowest level of evidence) to case-control
studies, ecological studies, cohort studies (considered
intermediate levels) to randomised clinical trials (RCTs)
and culminating in meta-analyses of RCTs (considered
the highest levels of evidence) [37]. Epidemiological
study designs are conceived within a hierarchy depending
on the degree of evidence attributed to the study design.
Table 1 summarises a system of evidence hierarchies pub-
lished by the Oxford Centre for Evidence-Based Medicine
(EBM) [37]. In clinical epidemiology, EBM has developed
standards on how to evaluate scientific studies for medical
decision-making. In the context of clinical medicine, this
objectification of medical knowledge through EBM was
initiated as part of a movement [38], opposed to the pre-
vailing clinical hierarchies. The evidence-based approach
has been discussed in many fields beyond medicine, for
instance in evidence-based policy or environmental man-
agement [39]. As the table shows, a substantial part of
approaches in environmental epidemiology does not
reach beyond an intermediate level of evidence in this
hierarchy. What has been conceived as an innovation in
hospital medicine, can bear different implications in
other domains, including HBM. The regulation and hier-
archisation of scientific evidence, which privileges the
RCT followed by cohort studies as the highest mode of
evidence, can seldom be met in environmental health
studies. With the recommendations for EBM, geographic
mapping can hardly provide sufficient evidence for an
environmental policy decision. For environmental issues,
this mode of evidence has significant repercussions to
concepts of precautionary action.
On the one hand, HBM holds the promise to better assess
actual doses and is therefore hoped to advance environ-
mental health studies within this evidence hierarchy and
provide more visibility as to environmental factors in ana-
lytical epidemiology. On the other hand, the contextual
value of descriptive studies and mapping in environmen-
tal sciences is often neglected, when the main reference
point resides in this formalised order of evidence hierar-
chies. Furthermore, error ranges and uncertainties in the
interpretation of biomarkers are substantial, in part as
biomarker concentrations vary between individuals and
are often not persistent over time; misclassification due to
error in exposure measurement may lead to underestima-
tion of the effect [31,40]. More general criticisms have
pointed to the limits of epidemiology in particular in
environmental health, concluding that, given the uncer-
tainties involved, a precautionary approach is needed
when it comes to environmental health risks [41-43].
At stake in the development of an evidence-based envi-
ronmental science, as envisioned also by some environ-
mental science initiatives [39], are precisely the modes of
proof and evidence in environmental health sciences. To
meet the conditions of proof, individual-level data and,
more importantly, randomised assignment of interven-
tions are called for. The following section will turn to the
example of an ethics case that evolved around the pursuit
of a rigorous experimental design in environmental
health research.
Ethical problematisations as societal issues
Environmental epidemiology, "experimental" studies and regimes of 
imperceptibility
In clinical and epidemiological research practice, ethical
issues are often solely dealt with at the level of participa-
tion, e.g. in terms of informed consent, confidentiality,
the right to end participation at any time, under reference
to individual decision autonomy [44]. Yet, another aspect
evolves around the issue of what kind of evidence is
demanded for environmental health measures. A much
debated example of an environmental health ethics case is
the lead paint abatement study conducted at the Kennedy
Krieger Institute affiliated with Johns Hopkins University
in Baltimore (USA) [45]. Lawsuits and a major ethics con-
troversy accompanied this intervention study, in which
public health researchers investigated the effects of abate-
ment procedures among children in a disadvantaged
Table 1: Evidence hierarchies for questions of therapy/prevention and aetiology/harm (abridged) [37]
Level of evidence Study type
1a Systematic reviews of randomized controlled trials
1b Individual randomized controlled trials
1c All or none randomized controlled trials
2a Systematic reviews of cohort studies
2b Individual cohort study or low quality randomized controlled trials
2c 'Outcomes' Research; ecological studies
3a Systematic review of case-control studies
3b Individual case-control study
4 Case-series (and poor quality cohort and case-control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'Environmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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housing area in Baltimore. The intervention trial was
designed to study whether less expensive abatement
methods had the same effects as to reducing elevated
blood lead levels.
The study raised a debate on the ethics of non-therapeutic
research, in particular with children. Parents sued the
responsible institute because they weren't adequately
informed about the aim of the study and potential risks to
their children. The judge put forward the argument that
the children were intentionally put at risk and used as
"measurement tools" in the study [46]. In the debate that
followed, public health researchers argued for a pragmatic
approach to ethics, since the proof for the effect of a
cheaper abatement method could in future benefit large
numbers of disadvantaged children, when informing
environmental policies in a situation of scarce resources
[47]. Others maintained that the experimental trial was
unethical, e.g. since landlords were deliberately encour-
aged to rent homes with known lead contamination to
families with children; research aimed at saving money
and the cost-benefit reasoning was seen as problematic in
itself [46]. This mode of public health research was criti-
cised for being more concerned with the quality of the
"experiment" than with the actual benefit or harm to par-
ticipating subjects.
Stating the lack of sufficient evidence from rigorous epide-
miological studies is problematic for chemicals with well
documented toxic effects such as lead. It has been viewed
as unethical to conduct environmental health studies at
the level of best evidence (randomised trial examining
cheaper interventions) instead of providing the best
abatement, similar as it is widely considered unethical to
continue a clinical trial after it has provided evidence for
the superiority of a treatment. Both the use of EBM in the
allocation of resources [48,49] and the principle of equi-
poise in clinical trials [50-53] have been subject to intense
debate in the past two decades.
While the researchers strived to generate knowledge at the
highest possible level of evidence according to the stand-
ards of the discipline, it was the experimental design to
achieve this that resulted in ethical controversy. This was
particularly sensitive because the tested hypothesis was
whether cheaper abatement was as efficient as more
expensive abatement. Yet in another twist to the ethics
debate, some epidemiologists held that it would be
unethical not to conduct such studies, because it would
preclude the allocation of resources to more people. At
stake in these ethical problematisations were the terms of
proof and the level of evidence that is considered justify-
ing the allocation of resources, when the distribution of
resources in environmental health is decided upon. These
involve trade-offs, which in this case centred on cost
aspects rather than on environmental risk.
The perceptibility of environmental risk in standard epi-
demiological methods is rather narrow, due to long time
lags for late effects and multiple interactions that are often
difficult to investigate. This also holds on an epistemolog-
ical level – due to the asymmetries in the ways false posi-
tives and false negatives are treated in the default
procedures of hypotheses testing in both epidemiology
and toxicology: the standard methodological tradition
gives the reduction of type I error with 95% significance
levels more emphasis than avoiding false negatives by
securing sufficient power [42,43]. Therefore, both the for-
mulation of the research question and the conditions
under which the null hypothesis (that there is no influ-
ence of the exposure to disease) can be rejected, for
instance the confidence level in relation to the power of a
study, are also matters of epistemological politics. For the
methodological limitations and the contingent invisibili-
ties of environmental health risks, Murphy introduces the
notion of "regimes of imperceptibility" [54]. The percep-
tibility of environmental health risks as scientific and soci-
etal issues depends on how the standards of proof are set.
In view of the ethical issues arising in prospective observa-
tional studies that would evaluate preventive interven-
tions, the implications of the very frameworks for
evidence and proof for science and policy action need to
be discussed; this cannot be resolved by science alone;
they require a broad debate on the conditions of proof
requested for action on a societal level. To account for
fields where no RCTs are possible, a protocol for observa-
tional studies [55] has been developed, similar to the idea
of the Cochrane collaboration; for environmental health,
these evidence criteria require further reflection and elab-
oration. The perceptibility of environmental health issues
will depend on how the concept of evidence is framed and
on how the burden of proof for environmental risks is dis-
tributed in society.
Biosocial shifts: from exposure assessment to markers of risk and 
susceptibility
This paper has so far mostly addressed the use of biomar-
kers of exposure in HBM. However the European Environ-
ment and Health Action Plan envisions a broader
understanding of HBM as the "monitoring activities in
human beings, using biomarkers, that focus on environ-
mental exposures, diseases and/or disorders and genetic
susceptibility, and their potential relationships" [11].
Extending beyond markers of exposure, biomarkers of dis-
ease and genetic susceptibility raise more and different
ethical and societal issues; these have far reaching impli-
cations for our understanding of environmental health as
well as for policy and regulation.Environmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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In a 2004 report, the Genomics Task Force of the US Envi-
ronmental Protection Agency (EPA) envisioned how individ-
ual genetic susceptibility could be integrated into future
policy and regulation. "If, for example, a genomics study
were to identify a susceptible population at risk due to
exposure to a contaminant at a Superfund site through a
correlation of genomic analysis of local populations and
measured or expected exposure levels, the Agency might
choose to reduce the RfD/RfC [inhalation reference con-
centration/oral reference dose] value and propose more
strict remediation measures. [...] Use of new genomics
tools could, however, limit the extent of remediation
measures by more accurately predicting the potential for
exposure of the sensitive population. Thus, genomics
tools may play a key role in determining intensity and
extent of clean-up practices and have large implications
for time and cost of such procedures" [56]. Thus, concepts
and management principles of environmental and occu-
pational health could change tremendously towards a dif-
ferential model of protection against environmental
pollutants: In this US report, individual and collective sus-
ceptibility profiles are envisioned to co-determine the
extent of clean-up. This may significantly alter the notion
of (environmental) equity and justice, as well as the
related regulatory politics.
On the level of societal effects, the rise of biomarker
assessments leads to more individualised accounts of
health risks, as it is measured via biomarkers together with
individual susceptibility. This trend can be viewed as fur-
ther fostering "biomedicalisation" [34] of environmental
health, as it shifts not only the site of monitoring to the
individuals, but also envisions environmental manage-
ment and decisions on clean-up as dependent on the
genetic susceptibility of those exposed to environmental
pollution.
While biomarker research is hoped to provide more pre-
cise assessment of combined exposures, it cannot offer
information on exposure sources and histories; as biomar-
kers measure individual uptake, they often remain unspe-
cific with respect to exposure. As the European Environment
and Health Action Plan states, "responses can then focus
either on exposure by reduction or elimination of the pol-
lutant or on health effects by prevention, early identifica-
tion or stopping the progression of disease. The responses
may also concentrate on the individual encouraging a
behavioural change or medical intervention"[11]. This
statement extends the responses to the individual; these
can include optimising and reducing other risk factors. It
is likely that the paradigm of risk factor epidemiology will
rather result in measures on the level of individual behav-
iour than in exposure reduction. The risk factor approach
has been extremely successful in western societies, as it
represents a framework open to a host of potential deter-
minants and therefore easily perceived as neutral. Risk fac-
tor epidemiology has proved successful in formally
integrating multifactorial causation and at the same time
fostering the primacy of individual decision autonomy,
which constitutes health as an issue to act upon individu-
ally [57].
Supplementing biomarkers of exposure by markers of
genetic susceptibility tends to further frame the effects of
exposure in terms of individual biology and, potentially,
individual responsibility. It is the mobilisation into indi-
vidual risk management that can be seen as part of an
emerging "biological citizenship" [26,27], as society, envi-
ronmental policies and the health care system appear
reconfigured according to bioscientific categories.
Human biosurveillance and civic epistemologies
The human biosurveillance of environmental chemicals
involves many stakeholders – government, industry,
researchers and non-governmental organisations and
individuals. In the European Union (EU), HBM is cur-
rently developed with the aim of providing integrated
health impact assessments by linkage to other environ-
mental and health data. Building a common platform is
envisioned in two steps: First, available data will be linked
at an aggregate level, e.g. by reference to geographic units.
Clusters of elevated exposure, dose and disease prevalence
can then be identified with geographic information sys-
tems as a descriptive tool. In a second step, individual-
level data will be used to test hypotheses by linkage to
established cohort studies or by the design of new follow-
up studies [12].
HBM has been evoked as a tool to monitor environmental
equity, in terms of detecting areas or population groups
with elevated exposures via biomarkers. The European
framework suggests biomonitoring as confirmatory when
(environmental) monitoring indicates exposure of a pop-
ulation: "Biomonitoring can then verify the actual expo-
sure and so provide better evidence for guiding
appropriate responses" [11]. Although the report stresses
that biomonitoring should complement exposure assess-
ment as part of an integrated framework, the envisioned
confirmatory use of HBM might result in transforming the
standards of proof demanded in environmental health;
thereby the indications to act upon exposures might be
shifting to the level of biomarkers.
Working on a standardised approach to support HBM,
bottom-up approaches have been drawn upon as well;
these survey actual practices, ethical frameworks, interpre-
tation of findings and policy issues [58,59]. The current
harmonisation efforts have revealed differences in regula-
tory concepts and practices of the member states; these
differences depend on whether they are part of occupa-Environmental Health 2008, 7(Suppl 1):S10 http://www.ehjournal.net/content/7/S1/S10
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tional or environmental health contexts. When assessing
inequalities in environmental exposures within and
between regions, this process faces not only different
methodologies but also different traditions of environ-
mental monitoring, health surveillance and medical
record keeping routines, which both reflect and produce
different local "civic epistemologies" [30].
As to harmonisation effort in a different field – that of
social statistics – input harmonisation and output harmo-
nisation have been discussed as possible instruments to
secure data comparability [60]. Here, input harmonisa-
tion has been understood as somewhat ideal data record-
ing system in a common political space, where data are
collected in identical formats. However this wouldn't
allow for regionally specific studies, because the context-
specific variables would no longer be available and locally
meaningful research may be precluded. Output harmoni-
sation secures comparability, yet allows for diversity as to
the variables that are collected. This experience from
social statistics and awareness of related implications for
civic epistemology could prove instrumental in keeping
the HBM system open enough to address locally relevant
environmental health inequities.
Conclusion
The shift of exposure monitoring towards the biosurveil-
lance of human populations involves fundamental
changes in the ways environment, health and disease are
conceptualised; this potentially leads to an individualisa-
tion of responsibilities for health risks and preventive
action. In developing the HBM platform as an infrastruc-
ture to secure environmental health equity, awareness of
the epistemological and societal frameworks both from
environmental science and epidemiology will be critical.
Science studies tools can help understand the epistemo-
logical and the societal stakes in the field of environmen-
tal health. Accounting for the different thought styles at
work in HBM can be of relevance in the decisions to be
made during implementation and validation as well as in
the translation of data to environmental policy. Attention
to the societal dimensions of biosurveillance is crucial,
when it comes to developing more participatory
approaches and applying HBM data in regulatory politics.
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